Ellsworth Advisors’s Corcept Therapeutics CORT Stock Holding History

Ellsworth Advisors’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,006	Closed	-$769K	–	170
2025 Q3	$769K	Buy	+10,006	New	+$724K	0.16%	119

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ellsworth Advisors's CORT Position: Q4 2025 in Review

Ellsworth Advisors sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 10,006 shares — an estimated $769K sold.

Ellsworth Advisors first reported a position in CORT in Q3 2025 and held it in 1 quarter. The position peaked at $769K in Q3 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

Ellsworth Advisors reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
Ellsworth Advisors sold 10,006 Corcept Therapeutics shares in Q4 2025, an estimated $769K.
Ellsworth Advisors first reported a position in Corcept Therapeutics in Q3 2025 and held it in 1 quarter.
Ellsworth Advisors's Corcept Therapeutics position peaked at $769K in Q3 2025.
389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Ellsworth Advisors's 13F filing for Q4 2025, filed 16 Jan 2026.